TERN

Merck's proposed acquisition of Terns Pharmaceuticals has cleared a key regulatory hurdle, with the Hart-Scott-Rodino (HSR) antitrust waiting period expiring without a challenge. This indicates U.S. antitrust regulators have no objection to the deal, moving it closer to completion. No revised deal terms or timeline for closing were mentioned in the article.